Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
66.51
+0.87 (+1.32%)
4:51:11 PM EDT: $66.49 -0.02 (-0.03%)
Products

Gilead Says Supplementary Biologics License Application Currently Under Review By FDA For Full Marketing Approval

Published: 03/25/2021 22:21 GMT
Gilead Sciences, Inc. (GILD) - European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-hziy for the Treatment of Metastatic Triple-negative Breast Cancer.
Gilead Sciences Inc - Supplementary Biologics License Application Currently Under Review by U.S. FDA for Full Marketing Approval.
Gilead Sciences Inc - Maa is Now Under Accelerated Review by Ema.